Skip to main content
Show — Main navigation
Hide — Main navigation
Home
About
The Chair
Inquiry Team
Expert Groups
Inquiry Intermediaries
Core Participants
Legal Representatives
Inquiry Memorial
Financial Reports
Approach
Terms of reference
List of Issues
Statements of approach
Inquiry Principles
News
News
Newsletter Archive
Reports
The Inquiry Report
Additional Compensation Report
First Interim Report
Second Interim Report
Compensation Framework Study
Evidence
Evidence
Hearings Archive
Compensation
Support
Support and FAQs
NHS Psychological Support
Support Groups
Infected Blood Support Schemes
Hepatitis C Testing
Contact us
Search
Accessibility Tool
Zoom in
Zoom out
Reset
Contrast
Accessibility tool
Listen
Get in touch
Quick Exit
Subscribe to Search results
Search
Sort your search results
Relevance
Title
Changed
The Public Records (Scotland) Act 1937 was passed.
Published on:
25 July, 2024
The Scottish Hospital Service Destruction of Records provided that hospital records (including blood transfusion records) had to be kept for 6 years after the patient's treatment at the hospital, or three years if the patient died at the hospital.
Published on:
25 July, 2024
The Retention and Disposal Schedule for England provided that records had to be kept 6 years after the conclusion of treatment or 6 years after the death of a patient.
Published on:
25 July, 2024
Regional Transfusion Directors' meeting recognised that "even if the incidence had reduced significantly since the last trial, because of self exclusion or for other reasons, the introduction of anti-HBc/ALT screening seemed very likely."
Published on:
24 July, 2024
Directors of Scottish National Blood Transfusion Service agreed that the UK Working Party on Transfusion Associated Hepatitis was the most appropriate body to pursue the implementation of surrogate testing.
Published on:
24 July, 2024
Dr Gunson was a proponent of the multi-centre study of Alanine Amino-transferase (ALT) and anti-hepatitis B core (anti-HBc) for the screening of blood donations in 1986.
Published on:
24 July, 2024
At the UK Directors Working Party meeting t had been agreed that "Screening should not be introduced at present especially in view of ARC [American Red Cross] postponement of core test start-up and reports of chaos in ALT screening programme."
Published on:
24 July, 2024
Dr Forrester stated in a letter that 'The position explicitly reached at the meeting [of UK Working Party on Transfusion-Associated Hepatitis] is to recommend research of no great significance or scientific interest because the prospect of research would serve to counter pressure from for example haemophiliacs and Haemophilia Directors to embark on an indirect and largely ineffective form of screening, which would also lose us a certain amount of perfectly harmless blood.'
Published on:
24 July, 2024
Dr Contreras wrote to Dr Smithies on the decision of the UK Working Party on Transfusion-Associated Hepatitis (WPTTH) to not fund a follow-up study. She stated that WPTTH had funded surrogate studies to determine NANBH rates in donors, and Dr Contreras wanted a follow-up study, not for patient safety, but to use transmission rates as a 'defence against "panic" requests to start surrogate screening'.
Published on:
24 July, 2024
At the meeting of the regional transfusion directors, Dr Gunson explained that a study beginning with transfused patients had been discussed but was felt to be "costly, difficult and not practical."
Published on:
24 July, 2024
The Working Party on Associated Hepatitis discussed the protocol for the anti-HBc/ALT screening trials.
Published on:
24 July, 2024
At a meeting of the SNBTS directors and haemophilia centre directors, Dr Forrester reported that in the US between 5 and 25 percent of transfusions led to the recipient contracting NANBH. It was said that the figure in the UK was approximately 2.5 percent and, in Scotland, that there were only one to five cases per annum.
Published on:
24 July, 2024
Material for the PMO report, supporting the view that transfusion associated NANBH was rare, "relatively benign" and generally not serious
Published on:
24 July, 2024
Dr Forrester wrote to Dr Moir seeking agreement in principle of CSO that funding for the scottish component of a research project can be sought
Published on:
24 July, 2024
Dr Moir wrote to Dr Forrester expressing reservations against providing funding for a research project involving one Scottish Transfusion Centre
Published on:
24 July, 2024
Dr Gunson wrote that it was incorrect that "no Scottish Centre was now being asked to participate" in the multi-centre study and that he was "dismayed" to read SNBT would be applying for funding for surrogate testing from 1 April 1988, as he had understood that "Scotland would not take unilateral action" in introducing surrogate testing without consultation with regional transfusion directors in England and Wales
Published on:
24 July, 2024
Professor Cash wrote to Dr Gunson, suggesting he should not take the content of the minutes in relation to surrogate testing "too seriously at this stage" as "the results of the UK study are unlikely to have a material affect [sic] on future operational practice."
Published on:
24 July, 2024
De Kernoff and Dr Colvin stated in a paper for the Haemophilia Working Party that the acute NANBH, appeared generally mild, though might sometimes be fatal, but the chronic NANBH seemed "very possible that there may be serious long-term sequelae"
Published on:
24 July, 2024
Dr Scott in an internal minute written to Dr McIntyre believed "we should prevent the BTS from doing a full scale introduction" of surrogate testing.
Published on:
24 July, 2024
Dr Gunson completed a funding application for a multi-centre study into surrogate testing and ALT.
Published on:
24 July, 2024
Pagination
First page
First
Previous page
Previous
…
Page
2025
Page
2026
Page
2027
Page
2028
Current page
2029
Page
2030
Page
2031
Page
2032
Page
2033
…
Next page
Next
Last page
Last